Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

10.39 -0.30 (-2.81%)
Streaming Delayed Price Updated: 12:23 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
1 Unprofitable Stock with Impressive Fundamentals and 2 We Find Risky
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
News headline image
3 Stocks Under $50 with Questionable Fundamentals
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Economy Supply Chain
News headline image
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q3 CY2025 results topping the market’s revenue expectations, but sales fell by 5.7% year on year to $14.54 million. Its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
What's Next: Ocular Therapeutix's Earnings Preview ↗
 
Via Benzinga
News headline image
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug ↗
Ocular Therapeutix Inc (NASDAQ: OCUL) stock surged after announcing plans to expedite FDA submission for its wet AMD treatment. 
Via Benzinga
News headline image
OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q3 2025 Results with Narrower-Than-Expected Loss ↗
OCULAR THERAPEUTIX reported mixed Q3 2025 results, with a slight revenue miss but a narrower-than-expected loss. The company highlighted progress in its AXPAXLI clinical pipeline. 
Via Chartmill
News headline image
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
OCUL Sales Drop 18% ↗
Via The Motley Fool
News headline image
OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q2 2025 Earnings Amid Clinical Progress ↗
OCULAR THERAPEUTIX reported mixed Q2 2025 results, missing revenue and EPS estimates. Stock dipped 6% pre-market but gained 28.5% over the past month. Progress in AXPAXLI™ SOL trials for wet AMD... 
Via Chartmill
News headline image
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Analyst Expectations For Ocular Therapeutix's Future ↗
 
Via Benzinga
News headline image
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings ↗
Ocular Therapeutix shares are trading lower by 13.3% Monday afternoon. The company reported worse-than-expected Q1 financial results. 
Via Benzinga
News headline image
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Ocular Therapeutix ↗
 
Via Benzinga
News headline image
Why Ocular Therapeutix Was Bumping Higher This Week ↗
Via The Motley Fool
News headline image
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside ↗
Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales. 
Via Benzinga
News headline image
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback ↗
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026. 
Via Stocktwits
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.